June 2026
Proprietary AI analyst is now available
Largest Life Sciences Tools Public Companies in the UK
Benchmark revenue and EBITDA valuation multiples for public comps like
Oxford Nanopore Technologies, Avacta Group, Diaceutics, SDI Group and Bioventix.
 | Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. | $2 | -1% | $2B | $1B | 4.9x | (12.7x) | ||
| Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea. | $1 | +127% | $428M | $425M | 2802.1x | (12.7x) | ||
| Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives. Geographically, it operates in UK, North America, Europe, and Asia and Rest of World. | $2 | +31% | $174M | $166M | 3.2x | 20.0x | ||
| SDI Group PLC designs and manufactures scientific and technology products for use by the life science, healthcare, astronomy, consumer manufacturing, and art conservation markets through Synoptics, the Artemis, the Opus instruments, and Astles Control systems brands. The Digital Imaging segment incorporates the Synoptics brands Syngene, Synbiosis, Synoptics Health and Fistreem, the Atik brands Atik Cameras, Opus, and Quantum Scientific Imaging, and the Graticules Optics business. The Sensors & Control segment combines Sentek, Astles Control Systems, Applied Thermal Control, Thermal Exchange, MPB Industries, and Chell Instruments businesses. It operates in the UK, Europe, America, Rest of Asia, and Rest of the world segments. It derives majority of its revenues from the United Kingdom. | $1 | -2% | $119M | $151M | 1.7x | 9.3x | ||
| Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country. | $22 | -39% | $116M | $109M | 6.2x | 8.0x | ||
| 4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States. | $7 | -44% | $114M | $91M | 72.7x | (6.2x) | ||
| GenIP PLC is engaged in Generative Artificial Intelligence (GenAI), and empowers organizations to evaluate and commercialize technology discoveries through two distinct to providing bespoke enhanced research reports assessing the market potential for new technological innovations by using the GenAI-driven proprietary software, InventionEvaluator, and providing executive recruitment services to match technology organizations with experienced executives and business leaders using the GenAI-driven proprietary software, Vortechs. Its operating segments are Invention Evaluator and Vortechs. It generates the majority of its revenue from the Invention Evaluator segment. | $0 | -84% | $2M | $1M | 2.2x | (1.1x) | ||
| Median | $2 | -2% | $119M | $151M | 4.9x | (1.1x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.